Simeon Taylor

Panomics LLC provides life sciences research reagents. It develops products and technologies for Parallel Quantitative Biology, a platform of reagents and products that enable the multiplex measurement of molecular events, such as intracellular pathway analysis, cell signaling and gene expression profiling, in a quantitative and scalable manner. The company was founded in 2000 and is headquartered in Fremont, CA.

Ingenuity Systems, Inc. provides intuitive web-based applications for quickly analyzing and accurately interpreting the biological meaning of genomics data. The company was founded in 1998 and is headquartered in Redwood City, CA.

Antipodean Pharmaceuticals, Inc. manufactures pharmaceutical products and provides pre clinical services. Its product MitoQ, which blocks mitochondrial oxidative damage and prevents cell death. The company was founded in 2002 and is headquartered in Menlo Park, CA.

Wildcat Discovery Technologies, Inc. provides commercial research and development services. The firm engages in development projects for materials for other applications, including gas storage, carbon capture, thermoelectric, and structural materials. Its products include electrolyte additives such as EM1, CM1, CM2, and EM2. The company was founded by Peter G. Schultz and Robert K. Downs in 2006 and is headquartered in San Diego, CA.

Marcadia Biotech, Inc. develops therapeutic products for diabetes and obesity. It is a biopharmaceutical company focuses on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. The company was founded in 2005 and is headquartered in Carmel, IN.

PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

MedPointe, Inc. develops, markets, and sells therapeutics. The company's products include respiratory, allergy, central nervous system, cough/cold, and pediatric products. The company was founded by James S. Burns and Anthony H. Wild in 2001 and is headquartered in Somerset, NJ.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA.

Moximed, Inc. develops minimally invasive, joint sparing solutions for patients with knee osteoarthritis. Its Osteoarthritis treatment can minimize joint pain, restore normal activity levels, and slow down disease progression. The company was founded by Anton G. Clifford in 2006 and is headquartered in Hayward, CA.

On Target Laboratories LLC develops precise and innovative small molecules whose goal is to target and illuminate cancer and other diseased tissue. The company is headquartered in Northbrook, IL.

Cellular Research, Inc. operates as a biotechnology research and development company. It offer Precise assays that provides quantitation of mRNA targets in single cells and small samples; precise predefined gene expression panels; and Pixel system, a detection platform for direct mRNA quantitation from single cells and rare samples. The company’s products are used in various applications that include gene expression validation, RNA-seq validation, pathway validation, and rare transcript detection. The company was founded by Stephen P. A. Fodor, Ari Chaney, Stephen R. Quake and Glenn Fu in 2011 and is headquartered in Menlo Park, CA.

Zavante Therapeutics, Inc. manufactures pharmaceutical products. Its product ZOLYD is an investigational, first-in-class epoxide antibiotic with a spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that threaten hospitalized patients. The company was founded by Cam L. Garner, Evelyn Ellis-Grosse and Theodore R. Schroeder in 2013 and is headquartered in San Diego, CA.

Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA.

Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL.

Recida Therapeutics, Inc. engages in the development of novel therapeutics. The company was founded by Yigong Ge, Aditya Kohli, and David A. Socks in 2016 and is headquartered in Menlo Park, CA.

MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN.

Kovina Therapeutics, Inc. is a pre-clinical stage biotechnology company based in Indianapolis, IN. The company has assembled a team of scientists and industry leaders with expertise in HPV and small molecule drug design to advance its pipeline of drug candidates. Kovina Therapeutics is developing first-in-class anti-viral therapeutics to treat human papillomavirus (HPV) related infections and associated cancers. The company was founded by Samy Meroueh, Zhijian Lu, Elliot Androphy. Kristin T. Sherman has been the CEO of the company since 2021.